Market capitalization | $4.86m |
Enterprise Value | $5.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.35m |
Free Cash Flow (TTM) Free Cash Flow | $-4.02m |
Cash position | $70.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Nymox Pharmaceutical Corp:
1 Analyst has issued a forecast Nymox Pharmaceutical Corp:
Dec '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
0%
0%
|
|
EBITDA | -8.34 -8.34 |
26%
26%
|
EBIT (Operating Income) EBIT | -8.35 -8.35 |
26%
26%
|
Net Profit | -8.84 -8.84 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Head office | Bahamas |
CEO | Paul Averback |
Founded | 1995 |
Website | www.nymox.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.